



CURRICULUM VITAE

PERSONAL INFORMATION	Daniela Verzella Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila via Vetoio, Coppito II L'Aquila, 67100, Italy daniela.verzella@univaq.it
CURRENT POSITION	RTDA, Type A fixed-term researcher
EDUCATION OTHER QUALIFICATIONS	PhD in Experimental Medicine and Endocrinology <i>April 2012: University of L'Aquila, Department of Biotechnological and Applied Clinical Sciences</i> Thesis: Role of <i>Gadd45b</i> in Hepatocarcinogenesis and in inflammation-driven liver cancer Advisors: Profs F. Zazzeroni and E. Alesse Master's in Medical Biotechnology, cum laude <i>September 2008: University of L'Aquila, Department of Biotechnological and Applied Clinical Sciences</i> Thesis: The tumor suppressor gene KCTD11 ^{REN} is a new transcriptional target of NF- κ B Advisors: Profs F. Zazzeroni and E. Alesse Bachelor's in Biotechnology, cum laude <i>October 2006: University of L'Aquila, Department of Biotechnological and Applied Clinical Sciences</i> Thesis: Role of inflammation in liver tumor initiation and development Advisors: Profs F. Zazzeroni and E. Alesse
ACADEMIC APPOINTMENTS	
CLINIC APPOINTMENTS	



TEACHING EXPERIENCE	<p>Metodologie avanzate nel laboratorio di emocoagulazione [D42775], module of Applied technical medical sciences Biomedical Laboratory techniques, first cycle degree.</p> <p>Metodologie Biomolecolari [DM0061], module of Biomedical Laboratory techniques Biotechnologies, first cycle degree.</p> <p>High Throughput metabolomics [DT0361] Applied Data Science, second cycle degree.</p>
RESEARCH ACTIVITIES	<p>The role of GADD45B, a NF-κB-mediated antiapoptotic gene, in haematological and solid tumors such as Acute Myeloid Leukemia (AML) and in Prostate Cancer (PCa). The therapeutic efficacy of DTP3, the novel D-tripeptide inhibitor of the GADD45B-MKK7 complex, across tumor cell lines and human primary cells underling the potential translation of this novel NF-κB-targeting approach into clinical benefit for patients. The role of Gadd45b in mediating the NF-κB-dependent anti-inflammatory and immunosuppressive signaling in cancer. The role of CES1/TGH, an NF-κB-regulated lipase, in driving metabolic adaptation in several solid tumors such as breast and ovarian cancer and prostate adenocarcinoma.</p>
RESPONSIBILITY IN ACADEMIC ACTIVITIES	
EDITORIAL BOARD, EDITORIAL ACTIVITIES, SOCIETY MEMBERSHIP	<p>Italian Society of Translational Medicine and Medical Professions (S.I.R.T.E.P.S.)</p>
SCIENTIFIC ACHIEVEMENTS BIBLIOMETRIC INDICATORS	<p>Scopus Author ID:55081773000 http://orcid.org/0000-0003-0492-5097 (Hirsch (H) Index, i10-Hirsch (H), normalized Index, total number of quotes, median number of quotes by article</p>
SELECTED PUBLICATIONS	<ul style="list-style-type: none"> • Low radiation environment switches the overgrowth-induced cell apoptosis toward autophagy. Fischietti M, Fratini E, Verzella D, Vecchiotti D, Capece D, Di Francesco B, Esposito G, Balata M, Ioannucci L, Sykes P, Satta L, Zazzeroni F, Tessitore A, Tabocchini MA, Alesse E. <i>Front Public Health</i> 2021 Jan 12;8:594789. doi:10.3389/fpubh.2020.594789. • Life, death, and autophagy in cancer: NF-κB turns up everywhere. Verzella D, Pescatore A, Capece D, Vecchiotti D, Ursini MV, Franzoso G, Alesse E, Zazzeroni F. <i>Cell Death & Disease</i> 2020 Mar 30;11(3):210. doi: 10.1038/s41419-020-2399-y. • NF-κB and mitochondria cross paths in cancer: mitochondrial metabolism and beyond. Capece D, Verzella D, Di Francesco B, Alesse E, Franzoso G, Zazzeroni F. <i>Semin Cell Dev Biol.</i> 2020 Feb; 98:118-128. doi: 10.1016/j.semcd.2019.05.021.



- **Preclinical toxicology and safety pharmacology of the first-in-class GADD45B/MKK7 inhibitor and clinical candidate, DTP3.** Tornatore L, Capece D, D'Andrea D, Begalli F, **Verzella D**, Bennett J, Acton G, Campbell E, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi M, Kaczmariski R, Gabriel I, Oakervee H, Kaiser M, Wechalekar A, Benjamin R, Apperley J, Auner H, Franzoso G. *Toxicol Rep.* 2019 Apr 19;6:369-379. doi: 10.1016/j.toxrep.2019.04.006.
- **Clinical proof of concept for a safe and effective NF- κ B-targeting strategy in multiple myeloma.** Tornatore L, Capece D, D'Andrea D, Begalli F, **Verzella D**, Bennett J, Acton G, Campbell E, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi M, Kaczmariski R, Gabriel I, Oakervee H, Kaiser M, Wechalekar A, Benjamin R, Apperley J, Auner H, Franzoso G. *Br J Haematol.* 2019 May;185(3):588-592. doi: 10.1111/bjh.15569.
- **Turning an old GADDget into a troublemaker.** Capece D, D'Andrea D, **Verzella D**, Tornatore L, Begalli F, Bennett J, Franzoso G. *Cell Death & Differentiation.* 2018 Mar;25(4):640-642. doi: 10.1038/s41418-018-0087-6.
- **GADD45 β loss ablates innate immunosuppression in cancer.** **Verzella D**, Bennett J, Fischietti M, Thotakura AK, Recordati C, Pasqualini F, Capece D, Vecchiotti D, D'Andrea D, Di Francesco B, De Maglie M, Begalli F, Tornatore L, Papa S, Lawrence T, Forbes SJ, Sica A, Alesse E, Zazzeroni F, Franzoso G. *Cancer Res.* 2018 Mar 1;78(5):1275-1292. doi: 10.1158/0008-5472.CAN-17-1833.
- **Cancer secretome and inflammation: The bright and the dark sides of NF- κ B.** Capece D, **Verzella D**, Tessitore A, Alesse E, Capalbo C, Zazzeroni F. *Semin Cell Dev Biol.* 2018 Jun; 78:51-61. doi: 10.1016/j.semcdb.2017.08.004.
- **Unlocking the NF- κ B Conundrum: Embracing Complexity to Achieve Specificity.** Begalli F, Bennett J, Capece D, **Verzella D**, D'Andrea D, Tornatore L, Franzoso G. *Biomedicines.* 2017 Aug 22;5(3). pii: E50. doi: 10.3390/biomedicines5030050.
- **MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.** Tessitore A, Ciccirelli G, Del Vecchio F, Gaggiano A, **Verzella D**, Fischietti M, Mastroiaco V, Vetuschi A, Sferra R, Barnabei R, Capece D, Zazzeroni F, Alesse E. *BMC Cancer.* 2016 Jan 5; 16:3. doi: 10.1186/s12885-015-2007-1.
- **Targeting the NF- κ B pathway in prostate cancer: a promising therapeutic approach?** **Verzella D**, Fischietti M, Capece D, Vecchiotti D, Del Vecchio F, Ciccirelli G, Mastroiaco V, Tessitore A, Alesse E, Zazzeroni F. *Curr Drug Targets.* 2016;17(3):311-20.



- **Macitentan inhibits TGF-beta pro-fibrotic action, blocking the signaling mediated by TBRI-ETRs complex in SSc dermal fibroblast.**
Cipriani P, Di Benedetto P, Ruscitti P, **Verzella D**, Fischietti M, Zazzeroni F, Liakouli V, Carubbi F, Berardicurti O, Alesse E, Giacomelli R. Arthritis Res Ther. 2015 Sep 10; 17:247. doi: 10.1186/s13075-015-0754-7.
- **KCTD11 tumor suppressor gene expression is reduced in prostate adenocarcinoma.**
Zazzeroni F, Nicosia D, Tessitore A, Gallo R, **Verzella D**, Fischietti M, Vecchiotti D, Ventura L, Capece D, Gulino A, Alesse E. Biomed Res Int. 2014; 2014:380398. doi: 10.1155/2014/380398.
- **A novel, non-canonical splice variant of the Ikaros gene is aberrantly expressed in B-cell lymphoproliferative disorders.**
Capece D, Zazzeroni F, Mancarelli MM, **Verzella D**, Fischietti M, Di Tommaso A, Maccarone R, Plebani S, Di Ianni M, Gulino A, Alesse E. PLoS One. 2013 Jul 9;8(7): e68080. doi: 10.1371/journal.pone.0068080.
- **The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages.**
Capece D, Fischietti M, **Verzella D**, Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F, Alesse E. Biomed Res Int. 2013; 2013:187204. doi: 10.1155/2013/187204.

PLACE AND DATE

L'Aquila, 27/02/21